

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**September 6, 2017**  
**MINUTES**

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, September 6, 2017.

**2. Welcome**

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Divya Ahuja, MD  
Philip Mubarak, MD  
Gregory Browning, MD

Tan Platt, MD  
Edward Behling, MD

Cheryl Hartvigsen, RPh  
Joni Bollinger, MD

**SC DHHS Staff:**

Jim Bradford, MD  
Janet Giles  
Constance Holloway, JD

**Magellan Medicaid Admin:**

Lisa Correll, PharmD

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, May 3, 2017**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

Company	Speaker	Drug/Class
Tris Pharma, Inc	Marsie Ross, PharmD	Attention Deficit Hyperactivity Disorder

**C. Drug Classes for Review**

Lisa Correll led the discussion for the following drug classes:

*Classes for Review*

Ophthalmics Anti-Inflammatory, Immunomodulators

*Classes for Re-Review*

Otic Antibiotics, Quinolones

Attention Deficit Hyperactivity Disorder

Skeletal Muscle Relaxants

The chart below represents the recommendations from the P & T Committee:

OPHTHALMICS, ANTI-INFLAMMATORY, IMMUNOMODULATORS	
Preferred	Non-Preferred
Restasis†	Xiidra

OTIC ANTIBIOTICS, QUINOLONES	
Preferred	Non-Preferred
Ciprodex Ciprofloxacin†	Cipro HC Ofloxacin Otovel

ATTENTION DEFICIT HYPERACTIVITY DISORDER	
Preferred	Non-Preferred
Adderall XR Amphetamine Salt Combo Dextroamphetamine Tab Focalin IR/XR† Guanfacine ER Kapvay ER† Methylphenidate IR/SR Methylphenidate ER† Quillivant XR Ritalin LA	Adderall Adzenys Amphet Salts Combo XR Daytrana Patch+ Dyanavel XR Susp Desoxyn Brand/Gen Dexmethylphenidate IR+/XR Dexodrine/Dexostat Dextroamphetamine ER caps Eveko

**ATTENTION DEFICIT HYPERACTIVITY DISORDER (cont)**

Strattera Vyvanse	Intuniv Mydayis Procentra Zenzedi Aptensio XR Concerta Brand Metadate CD/ER+ Methylin chew/soln Methylphenidate LA Quillichew ER Ritalin
----------------------	--

**SKELETAL MUSCLE RELAXANTS**

Preferred	Non-Preferred
Baclofen Chlorzoxazone Cyclobenzaprine IR (5/10mg) Dantrolene Sodium Methocarbamol Orphenadrine ER Tizanidine tabs	Amrix Cyclobenzaprine IR (7.5 mg) Dantrium Fexmid Brand/Gen Lorzone Metaxalone Parafon Forte Robaxin Soma/CMPD Brand/Gen+

‡ Indicates "Added as Preferred"

+ Indicates "Moved to Non-Preferred"

**5. Old Business**

None

**6. New Business**

Lisa presented new drugs to market. Call Center will be provided a copy of the DEA letter regarding Carisoprodol as well as the verbiage regarding 3 week duration for prescribers if issues/concerns regarding move to NP. P&T Committee was provided with information regarding the upcoming Behavioral Health Coalition (Sept 7<sup>th</sup>).

**7. Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

*Classes for Review*

Ophthalmics Anti-Inflammatory, Immunomodulators

*Classes for Re-Review*

Otic Antibiotics, Quinolones  
Attention Deficit Hyperactivity Disorder  
Skeletal Muscle Relaxants

**8. Closing Comments**

The next meeting will be held on Wednesday, November 1, 2017, at 4:00 p.m.

**9. Adjournment**

The meeting adjourned at p.m.